KR101165278B1 - 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현 - Google Patents

효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현 Download PDF

Info

Publication number
KR101165278B1
KR101165278B1 KR1020067006044A KR20067006044A KR101165278B1 KR 101165278 B1 KR101165278 B1 KR 101165278B1 KR 1020067006044 A KR1020067006044 A KR 1020067006044A KR 20067006044 A KR20067006044 A KR 20067006044A KR 101165278 B1 KR101165278 B1 KR 101165278B1
Authority
KR
South Korea
Prior art keywords
hpv45
protein
hpv
yeast
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067006044A
Other languages
English (en)
Korean (ko)
Other versions
KR20070029628A (ko
Inventor
제닌 티 브라이언
미셸 케이 브라운로
로렌 디 슐츠
카트린 우 얀센
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20070029628A publication Critical patent/KR20070029628A/ko
Application granted granted Critical
Publication of KR101165278B1 publication Critical patent/KR101165278B1/ko
Assigned to 머크 샤프 앤드 돔 엘엘씨 reassignment 머크 샤프 앤드 돔 엘엘씨 권리의 전부이전등록 Assignors: 머크 샤프 앤드 돔 코포레이션
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020067006044A 2003-09-29 2004-09-24 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현 Expired - Lifetime KR101165278B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (2)

Publication Number Publication Date
KR20070029628A KR20070029628A (ko) 2007-03-14
KR101165278B1 true KR101165278B1 (ko) 2012-07-23

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067006044A Expired - Lifetime KR101165278B1 (ko) 2003-09-29 2004-09-24 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현

Country Status (33)

Country Link
US (2) US7250170B2 (https=)
EP (1) EP1673106B1 (https=)
JP (4) JP5451960B2 (https=)
KR (1) KR101165278B1 (https=)
CN (1) CN1859923B (https=)
AR (2) AR045804A1 (https=)
AT (1) ATE435029T1 (https=)
AU (1) AU2004277934B2 (https=)
BE (1) BE2015C072I2 (https=)
BR (1) BRPI0414845B8 (https=)
CA (1) CA2539168C (https=)
CY (2) CY1110525T1 (https=)
DE (1) DE602004021828D1 (https=)
DK (1) DK1673106T3 (https=)
ES (1) ES2327530T3 (https=)
FR (1) FR15C0083I2 (https=)
HU (1) HUS1500063I1 (https=)
IL (1) IL174458A (https=)
IS (1) IS2694B (https=)
LT (2) LTPA2015049I1 (https=)
LU (1) LU92902I2 (https=)
MX (1) MXPA06003457A (https=)
MY (1) MY140664A (https=)
NL (1) NL300776I1 (https=)
NO (3) NO339932B1 (https=)
NZ (1) NZ545834A (https=)
PL (1) PL1673106T3 (https=)
PT (1) PT1673106E (https=)
RU (1) RU2360001C2 (https=)
SI (1) SI1673106T1 (https=)
TW (1) TWI350853B (https=)
WO (1) WO2005032586A1 (https=)
ZA (1) ZA200601961B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
MY148656A (en) * 2004-03-24 2013-05-15 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast.
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
EP2479187A1 (en) 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
CN104288763B (zh) 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
EP2722389B1 (en) 2011-06-15 2018-03-07 Hong Jin Kim Method for enhancing the production yield of human papillomavirus l1 protein
RU2610174C2 (ru) 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN107002085A (zh) * 2014-09-11 2017-08-01 卡迪拉保健有限公司 具有优异免疫学特性的优异的人乳头瘤病毒抗原和含有其的疫苗
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｐｖワクチン
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
DE69732378D1 (de) * 1997-05-27 2005-03-03 Hanil Synthetic Fiber Co Ltd Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
HUP0103091A3 (en) * 1998-08-14 2002-03-28 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
DE69924007T2 (de) * 1998-12-23 2006-04-06 Merck & Co., Inc. Neutralsierungs-assay, das humane papillomavirus-ähnliche partikel verwendet
EP1212358B1 (en) * 1999-08-25 2004-12-15 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
HK1056195B (en) 2000-07-21 2007-06-22 Glaxo Group Limited Codon-optimized papilloma virus sequences
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101080628B1 (ko) 2003-03-24 2011-11-08 머크 샤프 앤드 돔 코포레이션 효모에서 ｈｐｖ 31 ｌ1의 최적 발현

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, Vol. 73, pp.4972-4982 (1999.06.)
Vaccine, Vol. 21, pp.1539-1547 (2003.03.28)

Also Published As

Publication number Publication date
IS2694B (is) 2010-11-15
JP2007507207A (ja) 2007-03-29
MXPA06003457A (es) 2006-06-05
JP2011152137A (ja) 2011-08-11
KR20070029628A (ko) 2007-03-14
ATE435029T1 (de) 2009-07-15
EP1673106B1 (en) 2009-07-01
IL174458A (en) 2014-06-30
NO339932B1 (no) 2017-02-20
MY140664A (en) 2010-01-15
US20080138361A1 (en) 2008-06-12
HUS1500063I1 (hu) 2016-02-29
BRPI0414845A (pt) 2006-11-21
NO20061876L (no) 2006-04-28
WO2005032586A1 (en) 2005-04-14
CY2015050I1 (el) 2016-06-22
TW200521233A (en) 2005-07-01
US7482015B2 (en) 2009-01-27
AR045804A1 (es) 2005-11-16
JP5451960B2 (ja) 2014-03-26
US7250170B2 (en) 2007-07-31
JP2016136947A (ja) 2016-08-04
CY2015050I2 (el) 2016-06-22
PL1673106T3 (pl) 2009-12-31
CA2539168A1 (en) 2005-04-14
CY1110525T1 (el) 2015-04-29
CN1859923B (zh) 2012-09-05
AR077396A2 (es) 2011-08-24
EP1673106A1 (en) 2006-06-28
BRPI0414845B1 (pt) 2020-10-13
IL174458A0 (en) 2006-08-01
CA2539168C (en) 2011-05-31
NL300776I2 (https=) 2015-12-29
SI1673106T1 (sl) 2009-12-31
LU92902I2 (fr) 2016-03-08
TWI350853B (en) 2011-10-21
DE602004021828D1 (de) 2009-08-13
CN1859923A (zh) 2006-11-08
RU2006114701A (ru) 2007-11-10
FR15C0083I2 (fr) 2016-11-25
IS8362A (is) 2006-03-20
DK1673106T3 (da) 2009-11-09
NZ545834A (en) 2009-02-28
FR15C0083I1 (fr) 2016-08-01
AU2004277934B2 (en) 2009-09-17
RU2360001C2 (ru) 2009-06-27
AU2004277934A1 (en) 2005-04-14
BRPI0414845B8 (pt) 2021-06-15
BE2015C072I2 (https=) 2023-12-14
JP2014221052A (ja) 2014-11-27
NO2022051I1 (no) 2022-11-30
LTC1673106I2 (lt) 2017-05-10
ES2327530T3 (es) 2009-10-30
PT1673106E (pt) 2009-09-22
LTPA2015049I1 (lt) 2016-01-11
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
NL300776I1 (https=) 2015-12-29
US20060240040A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
KR101165278B1 (ko) 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현
KR101170654B1 (ko) 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060328

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090923

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110607

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120517

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120706

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120709

End annual number: 3

Start annual number: 1

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120711

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 4

End annual number: 4

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20160425

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160629

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170629

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 13

End annual number: 13